Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.70 | $1M | -$9M |
| 2025 Q4 | -4.01 | $11M | -$99M |
| 2025 Q3 | -1.27 | $0 | -$18M |
| 2025 Q2 | -4.93 | $0 | -$22M |
| 2025 Q1 | -0.78 | $0 | -$5M |
| 2024 Q4 | -0.92 | $0 | -$4M |
| 2024 Q3 |
| -0.15 |
| $0 |
| $19M |
| 2024 Q2 | -0.16 | $0 | -$9M |